Listing a plan does not confirm GLP-1 medication coverage
Sterile injectables and cold chain expansion Retatrutide remains an injectable peptide drug
Meet our clinical team Not sure which treatment is right for you
These innovations suggest that as researchers continue to refine and expand the pharmacological profiles of GLP-1RAs, their efficacy across multiple therapeutic domains will likely continue to increase, paving the way for broader applications and improved patient outcomes
10 Without behavior change, most of the lost weight will come back within 12 months of stopping the medication
In such cases, GLP-1 hormone can help contribute to glucose control by stimulating glucose-dependent insulin release, reducing glucagon secretion, slowing gastric emptying, and eventually enhancing satiety